background
product
human
monoclon
antibodi
exhibit
broadli
neutral
activ
need
prevent
infect
howev
antibodi
gener
till
date
isol
antibodi
hybridoma
technolog
cumbersom
process
fewer
yield
loss
unstabl
slowli
grow
clone
may
uniqu
bind
specif
often
occur
clone
propag
strongli
posit
clone
often
lost
avoid
process
describ
paper
wherein
combin
strategi
ebv
transform
recombin
dna
technolog
construct
human
singl
chain
variabl
fragment
scfv
third
variabl
region
clade
c
envelop
result
antigen
specif
phage
librari
clone
construct
enrich
antibodi
secret
ebv
transform
cell
ligat
digest
scfv
dna
phagemid
vector
bio
pan
consensu
c
b
peptid
follow
random
select
clone
identifi
clone
show
reactiv
phage
elisa
dna
fingerprint
analysi
sequenc
show
clone
distinct
express
posit
clone
test
sdspage
western
blot
scfv
show
crossreact
clade
c
b
peptid
show
reactiv
unrel
peptid
elisa
preliminari
neutral
assay
indic
vari
degre
neutral
clade
c
b
virus
ebv
transform
follow
antigen
select
line
identifi
specif
binder
enabl
select
phage
unclon
line
scfv
gener
thu
avoid
problem
hybridoma
technolog
moreov
clone
pretest
antigen
bind
compar
small
librari
suffic
select
consider
number
uniqu
antigen
bind
phage
select
phage
clone
propag
clonal
manner
conclus
strategi
effici
use
cost
effect
gener
divers
recombin
antibodi
first
studi
gener
scfv
clade
c
rapid
increas
number
human
immunodefici
viru
infect
individu
worldwid
far
met
littl
success
slow
prevent
progress
pandem
diseas
order
use
broadli
neutral
antibodi
effect
reagent
passiv
immunotherapi
slow
halt
diseas
progress
infect
individu
immunogen
design
vaccin
prevent
infect
gener
larg
number
human
specif
monoclon
antibodi
desir
although
human
broadli
neutral
antibodi
bnab
exist
antibodi
limit
reactiv
nonclad
b
virus
respons
infect
worldwid
bnab
exist
far
effect
clade
c
virus
includ
antibodi
caprisa
cohort
recent
isol
monoclon
antibodi
order
evalu
util
combat
infect
tackl
problem
pose
extens
divers
essenti
gener
larg
panel
human
antibodi
differ
specif
may
necessari
evalu
sever
antibodi
find
rare
highli
effect
molecul
method
use
gener
human
monoclon
antibodi
includ
hybridoma
technolog
recombin
technolog
phage
display
recent
employ
techniqu
singl
b
cell
sort
follow
amplif
heavi
light
chain
gene
gener
antibodi
convent
hybridoma
technolog
adequ
enough
meet
challeng
assess
larg
number
human
monoclon
antibodi
infect
individu
variou
stage
clinic
cours
approach
problem
combin
antigen
specif
preselect
ebv
transform
b
cell
construct
phage
librari
phage
display
scalabl
method
antibodi
product
wide
varieti
antigen
investig
use
technolog
product
antibodi
desir
isotyp
specif
affin
research
clinic
industri
applic
antibodi
gene
variabl
region
amplifi
express
surfac
filament
bacteriophag
fusion
protein
number
antibodi
produc
singl
librari
express
produc
prokaryot
system
major
drawback
technolog
requir
construct
larg
size
phage
librari
optimum
divers
divers
librari
primarili
determin
success
isol
desir
antibodi
construct
larg
librari
requir
number
ligat
electropor
reaction
screen
posit
clone
librari
gener
requir
least
three
seven
round
biopan
select
specif
bind
clone
also
difficult
maintain
larg
size
librari
keep
factor
mind
describ
simpl
effici
method
product
human
monoclon
antibodi
use
combin
approach
ebv
transform
antigen
preselect
phage
display
technolog
similar
approach
previous
use
kempf
et
al
isol
fab
adopt
modifi
strategi
isol
first
time
human
scfv
ebv
transform
lymphocyt
clade
c
infect
patient
method
use
produc
larg
panel
viral
specif
phage
librari
less
time
cost
effect
manner
limit
number
monoclon
antibodi
gener
clade
c
predomin
subtyp
worldwid
india
region
import
target
induc
neutral
antibodi
differ
strain
exhibit
high
degre
sequenc
variabl
structur
conserv
region
envelop
interact
coreceptor
studi
construct
scfv
librari
ebv
transform
b
cell
infect
patient
reactiv
third
variabl
region
clade
c
plasma
sampl
patient
previous
test
found
exhibit
cross
neutral
activ
standard
panel
pseudovirus
differ
clade
tabl
also
cross
reactiv
bind
antibodi
clade
c
b
peptid
modifi
strategi
use
employ
ebv
transform
antigen
preselect
follow
phage
librari
construct
enabl
success
select
human
monoclon
recombin
scfv
specif
antigen
construct
human
scfv
phage
librari
antigen
preselect
b
cell
led
effici
cost
effect
approach
product
scfv
plasma
antibodi
infect
patient
display
neutral
activ
virus
subtypea
b
c
tabl
plasma
sampl
also
show
cross
subtypeb
c
bind
reactiv
context
loop
direct
antibodi
figur
total
million
pbmc
isol
hivinfect
patient
ebv
transform
well
well
cultur
plate
figur
week
cultur
screen
first
screen
presenc
antibodi
well
show
high
bind
reactiv
od
cell
posit
well
expand
well
plate
second
screen
cell
well
show
bind
od
expand
sixwel
plate
pool
final
transfer
flask
final
screen
cell
flask
cell
show
high
reactiv
od
tabl
posit
enrich
cell
process
recombin
scfv
gener
total
rna
enrich
antibodi
produc
b
cell
patient
isol
total
rna
revers
transcrib
cdna
use
random
hexam
oligo
dt
cdna
synthesi
process
shown
effect
either
alon
primer
also
enhanc
chanc
amplif
antibodi
gene
even
amount
rna
low
total
combin
use
amplifi
heavi
light
chain
vh
vl
among
combin
heavi
chain
success
amplifi
heavi
chain
preferenti
express
less
express
figur
kappa
light
chain
combin
success
amplifi
express
almost
level
except
rel
less
express
figur
heavi
chain
light
chain
pool
made
mix
equal
concentr
combin
irrespect
express
level
combin
heavi
chain
equal
probabl
combin
light
chain
vice
versa
avoid
predomin
express
one
antibodi
subclass
final
new
combin
antibodi
particular
antigen
natur
elicit
natur
cours
infect
final
pull
pcr
perform
use
forward
revers
primer
scfv
ligat
vector
contain
noti
site
figur
ligat
product
transform
use
calcium
chlorid
mediat
transform
incub
time
heat
shock
treatment
transform
maintain
maximum
min
avoid
repetit
similar
type
clone
librari
obtain
transform
coloni
per
plate
total
coloni
obtain
digest
scfv
dna
ligat
phagemid
vector
ligat
dna
transform
ecoli
check
divers
antibodi
librari
randomli
select
clone
unselect
librari
amplif
scfv
pcr
follow
digest
compar
dna
fingerprint
pattern
show
clone
distinct
clone
clone
show
ident
dna
fingerprint
pattern
figur
confirm
divers
antibodi
fragment
dna
sequenc
analysi
randomli
select
scfv
clone
unselect
librari
show
high
divers
clone
ie
librari
heavi
chain
vh
sequenc
show
limit
divers
preferenti
repres
vh
sequenc
combin
repres
ighd
gene
except
divers
vl
paratop
also
limit
repres
except
one
occurr
tabl
size
librari
small
one
round
biopan
done
c
b
peptid
forti
clone
randomli
select
check
figur
schemat
overview
strategi
use
construct
antigen
specif
phage
librari
peripher
blood
mononuclear
cell
pbmc
isol
antiretrovir
drug
patient
whose
plasma
exhibit
neutral
activ
panel
virus
also
display
cross
clade
reactiv
antibodi
bind
potenti
pbmc
subject
ebv
transform
well
cultur
plate
well
show
high
level
antibodi
select
expand
well
stage
six
well
stage
well
show
high
titr
ab
pool
togeth
cultur
flask
total
rna
isol
antigen
specif
enrich
b
cell
cdna
synthesis
heavi
light
chain
amplifi
scfv
construct
clone
phagemid
vector
scfv
phage
librari
clone
construct
bind
show
posit
phage
elisa
peptid
figur
four
clone
randomli
select
elisa
purifi
phage
bind
specif
scfv
check
phage
well
plate
peg
precipit
purifi
phage
well
elisa
pure
phage
elisa
bind
assay
show
similar
result
three
clone
exhibit
almost
similar
bind
format
elisa
one
clone
lower
bind
reactiv
pure
phage
elisa
although
complet
lost
data
shown
dna
fingerprint
analysi
use
follow
sequenc
reveal
clone
distinct
tabl
distinct
anti
scfv
final
select
show
crossreact
peptid
show
reactiv
unrel
peptid
one
round
biopan
found
suffici
get
posit
scfv
clone
divers
antigen
bind
clone
show
positivitybind
phage
elisa
process
solubl
scfv
express
induct
iptg
induct
periplasm
lysat
inclus
bodi
cultur
supernat
whole
cell
extract
prepar
analys
scfv
express
reduc
sdspage
scfv
fusion
protein
found
express
cell
lysat
cultur
supernat
periplasm
extract
highest
express
inclus
bodi
scfv
express
also
observ
uninduc
cultur
figur
scfv
express
e
coli
cell
induc
h
mm
iptg
total
million
pbmc
isol
number
cell
plate
per
well
forti
eight
well
subject
ebv
transform
well
success
transform
transform
effici
approx
well
show
posit
bind
od
peptid
expand
well
stage
antibodi
fragment
purifi
periplasm
extract
purifi
product
analys
sdspage
scfv
protein
express
differ
elut
fraction
figur
protein
sampl
concentr
use
ultrafiltr
column
ambion
cut
express
scfv
fusion
protein
kd
periplasm
extract
confirm
western
blot
cell
lysat
use
neg
control
figur
function
activ
newli
gener
clone
assess
bind
peptid
clade
c
b
elisa
scfv
show
specif
bind
peptid
figur
addit
scfv
bind
unrel
peptid
like
mper
id
loop
hiv
peptid
pool
unrel
virus
bsa
purifi
scfv
test
viral
neutral
potenti
panel
pseudovirus
clade
b
c
virus
tabl
demonstr
studi
strategi
success
yield
recombin
human
scfv
region
use
pool
antigen
select
ebv
transform
b
lymphocyt
phage
display
technolog
use
preselect
b
cell
produc
antibodi
phage
scfv
librari
construct
prove
effici
strategi
isol
specif
clone
moreov
approach
prevent
loss
unstabl
slowli
grow
clone
may
use
uniqu
bind
specif
often
occur
clone
propag
stringenc
initi
stage
help
elimin
fals
posit
clone
begin
well
stage
final
screen
cell
flask
select
well
high
bind
reactiv
expans
final
phage
librari
construct
approach
obtain
phage
librari
adequ
number
bind
clone
amplif
heavi
chain
gene
show
preferenti
express
corrobor
previou
report
antibodi
preferenti
exhibit
gene
usag
well
establish
infect
gene
less
preferenti
use
sequenc
data
observ
twenti
nine
randomli
select
clone
ebv
transform
cell
librari
exhibit
gene
usag
suggest
librari
may
bias
toward
antigen
specif
healthi
individu
gene
frequent
use
use
low
percentag
antibodi
http
imgtcinesfr
light
chain
show
preferenti
gene
usag
light
chain
success
amplifi
heavi
chain
amplif
bias
toward
express
set
heavi
chain
gene
avoid
predomin
express
one
subset
gene
phage
librari
took
equal
concentr
heavi
chain
gene
turn
increas
chanc
new
combin
express
natur
infect
success
isol
posit
clone
higher
affin
specif
possibl
librari
divers
less
number
clone
incomplet
scfv
sequenc
phage
carri
incomplet
scfv
number
overwhelm
librari
multistep
pan
therebi
presenc
full
size
insert
decreas
common
problem
phage
librari
interestingli
librari
exhibit
divers
clone
clone
complet
scfv
figur
b
might
optimum
incub
time
min
maintain
transform
process
reduc
chanc
repetit
clone
addit
combin
site
contain
vector
use
librari
construct
may
reduc
elimin
chanc
get
incomplet
scfv
sequenc
restrict
enzym
site
rare
present
scfv
dna
sequenc
furthermor
none
clone
intern
site
stringenc
biopan
also
reduc
number
fals
posit
clone
initi
phage
allow
bind
plastic
plate
next
coat
milk
follow
bsa
final
onto
pool
coat
unrel
antigen
plate
stringenc
reduc
number
nonspecif
phage
binder
made
screen
process
conveni
specif
kempf
et
al
use
similar
strategi
ebv
transform
construct
fab
librari
clone
isol
three
fab
one
round
biopan
score
posit
clone
howev
less
probabl
select
cell
posit
bind
well
stage
also
includ
well
low
binder
od
therefor
select
well
high
bind
reactiv
od
stage
phage
librari
construct
reduc
number
fals
posit
clone
enrich
specif
cell
sever
report
gener
scfv
differ
sourc
like
pbmc
bone
marrow
tonsil
hybridoma
none
employ
ebv
transform
antigen
specif
cell
gener
scfv
phage
librari
gener
phage
librari
ebv
transform
line
preselect
antigen
use
laboratori
limit
resourc
antibodi
product
tradit
hybridoma
technolog
cost
rang
cost
incur
post
ebv
immort
step
like
fusion
clone
strategi
requir
expens
process
electropor
cost
cuvett
instrument
mainli
limit
construct
phage
librari
larg
size
divers
also
elimin
larg
number
biopan
round
follow
cumbersom
screen
process
small
librari
easi
maintain
produc
routin
use
calcium
chlorid
mediat
transform
first
time
gener
human
scfv
clade
c
antigen
preselect
phage
librari
serv
adequ
sourc
posit
clone
combin
ebv
transform
select
immort
line
exhibit
desir
antigen
bind
characterist
phage
display
technolog
provid
use
strategi
specif
recombin
antibodi
gener
studi
valid
gener
recombin
librari
power
tool
gener
divers
recombin
antibodi
seroposit
patient
enrol
construct
scfv
phage
librari
recruit
obtain
written
inform
consent
depart
medicin
aiim
new
delhi
studi
approv
institut
ethic
committe
whole
blood
collect
edta
vaccutain
plasma
separ
whole
blood
aliquot
store
test
peripher
blood
mononuclear
cell
pbmc
separ
phycol
hypaqu
centrifug
process
immedi
ebv
transform
plasma
sampl
patient
previous
test
found
exhibit
good
neutral
potenti
divers
panel
virus
tabl
also
test
presenc
bind
antibodi
data
shown
figur
neutral
effici
plasma
test
standard
panel
pseudovirus
clade
b
c
obtain
nih
aid
research
refer
reagent
program
tzmbl
assay
standard
panel
pseudovirus
categor
tier
tier
base
decreas
order
suscept
neutral
known
monoclon
antibodi
neutral
assay
carri
tissu
cultur
plate
briefli
heat
inactiv
plasmapurifi
scfv
differ
dilut
duplic
ad
tcid
viru
incub
h
cell
control
well
contain
cultur
media
viru
control
well
contain
cultur
media
viru
test
parallel
rest
procedur
describ
calcul
tcid
scfv
hepb
scfv
hepat
b
surfac
antigen
human
antibodi
parvoviru
protein
use
neg
control
dilut
test
plasma
percent
neutral
calcul
base
rel
luminesc
unit
rlu
presenc
plasma
divid
viru
control
cell
control
valu
subtract
plasma
rlu
valu
background
cutoff
neutral
titer
titer
determin
plasma
sampl
viru
plot
percentag
neutral
dilut
plasma
test
nonlinear
regress
straight
line
drawn
method
least
squar
reciproc
titer
extrapol
experi
perform
duplic
repeat
least
twice
mean
titer
calcul
antibodi
content
seroposit
plasma
sampl
supernat
ebv
transform
pbmc
cultur
differ
stage
determin
use
peptid
elisa
thirti
five
mer
peptid
ctrpnnntrksirigpgqtfyatgdi
igdirqahc
ctrpnnntrksihigpgrafi
ttgeiigdirqahc
synthesis
sigma
aldrich
usa
base
consensu
sequenc
peptid
coat
onto
well
nuncimmuno
plate
nunc
cat
use
antigen
coat
buffer
mm
na
co
mm
nahco
mm
nan
ph
overnight
plate
wash
use
phosphat
buffer
salin
pbst
thrice
use
plate
washer
plate
block
fetal
calf
serum
incub
h
follow
block
wash
heat
inactiv
plasma
dilut
supernat
ebv
transform
pbmc
cultur
ad
well
incub
wash
pbst
bound
specif
antibodi
detect
addit
alkalinephosphatas
conjug
antihuman
igg
fc
pbst
immun
complex
reveal
apsubstr
dae
buffer
colorimetr
reaction
stop
addit
naoh
optic
densiti
read
nm
id
titer
calcul
plasma
sampl
peptid
plot
absorb
nm
dilut
plasma
sampl
test
nonlinear
regress
straight
line
drawn
method
least
squar
id
titer
extrapol
cell
line
compris
ebv
transform
human
lymphoblastoid
cell
secret
ebv
supernat
ebv
transform
human
b
cell
obtain
cell
line
american
type
cell
cultur
cat
cell
grown
tissu
cultur
flask
cellsml
co
complet
rpmi
media
day
viral
supernat
centrifug
g
filter
filter
peripher
blood
mononuclear
cell
pbmc
cellswel
patient
ebv
transform
mix
viral
supernat
plate
cultur
polyclon
b
cell
activ
cpg
enhanc
ebv
infect
b
cell
transform
csa
plate
incub
co
incub
overnight
next
day
cell
fed
complet
medium
contain
csa
cpg
cultur
fed
twice
per
week
half
cultur
supernat
replac
fresh
complet
media
csa
cpg
two
week
cultur
b
cell
well
plate
screen
presenc
antibodi
peptid
bind
elisa
describ
posit
b
cell
clone
expand
well
plate
screen
rd
th
week
posit
clone
transfer
six
well
plate
pool
expand
flask
tabl
total
rna
specif
antibodi
produc
b
cell
flask
stage
isol
trizol
reagent
sigma
usa
revers
transcrib
cdna
use
revers
aid
mmulv
revers
transcriptas
fermenta
usa
total
ng
rna
revers
transcrib
reaction
volum
contain
random
hexam
oligodt
rnase
inhibitor
dissolv
rt
buffer
rna
heat
min
immedi
chill
ice
least
five
minut
follow
addit
reaction
mixtur
tube
incub
min
min
quickli
chill
ice
store
heavi
chain
variabl
region
gene
amplifi
use
total
combin
forward
primer
revers
primer
repres
human
immunoglobulin
subfamili
light
chain
kappa
total
combin
use
forward
primer
revers
primer
describ
previous
total
independ
reaction
perform
gener
variabl
region
heavi
light
chain
heavi
chain
primer
includ
sfii
site
light
chain
primer
includ
noti
site
light
chain
primer
includ
part
linker
region
gli
ser
compat
heavi
chain
primer
variabl
heavi
region
amplifi
use
hot
start
taq
dna
polymeras
fermenta
pcr
reaction
contain
cdna
primer
pmole
forward
revers
pcr
reaction
perform
cycl
min
initi
denatur
min
anneal
min
extens
min
use
eppendorf
master
cycler
light
chain
variabl
region
amplifi
similar
protocol
except
anneal
temperatur
use
variabl
region
gene
purifi
agaros
gel
use
gel
extract
kit
qiagen
germani
equimolar
mixtur
pool
heavi
light
chain
dna
use
second
round
assembl
pcr
assembl
pcr
reaction
cycl
time
min
sec
sec
min
assembl
reaction
perform
use
pfu
dna
polymeras
without
primer
full
length
scfv
amplifi
use
pull
pcr
reaction
use
taq
dna
polymeras
follow
primer
ptfw
cct
ttc
tat
gcg
gcc
cag
ccg
gcc
atg
gcc
ptrv
cag
tca
ttc
tcg
act
tgc
ggc
cgc
acg
min
anneal
extens
min
final
extens
min
scfv
agaros
gel
purifi
use
gel
extract
kit
qiagen
germani
scfv
dna
fragment
vector
digest
noti
sfii
new
england
biolab
usa
respect
digest
scfv
dna
fragment
vector
gel
purifi
use
gel
extract
kit
qiagen
germani
scfv
dna
ligat
vector
molar
ratio
use
dna
ligas
new
england
biolab
usa
ligat
dna
transform
chemic
compet
cell
ecoli
place
ice
follow
heat
shock
treatment
second
chill
ice
min
next
media
ad
incub
rotat
shaker
rpm
min
transform
cell
plate
medium
agar
plate
contain
ampicillin
mgml
glucos
incub
overnight
follow
day
coloni
scrape
medium
glycerol
store
sequenc
assembl
scfv
confirm
autom
abi
prism
sequenc
use
gene
specif
primer
phage
rescu
infect
helper
phage
follow
precipit
pegnacl
resuspens
pb
titrat
determin
phage
concentr
phage
subject
singl
round
enrich
biopan
pan
procedur
carri
immuno
microwel
plate
plate
coat
peptid
nahco
ph
overnight
phage
librari
phage
incub
milk
coat
well
remov
nonspecif
binder
one
hour
unbound
phage
transfer
peptid
coat
well
min
rt
unbound
phage
elimin
wash
time
pb
contain
tween
bound
phage
elut
glycin
ph
min
rt
elut
phage
neutral
tri
hcl
ph
immedi
infect
onto
od
min
min
shake
cell
spun
plate
agar
contain
ampicillin
mgml
glucos
individu
coloni
pick
grown
well
steril
cultur
plate
corn
glycerol
stock
made
store
individu
coloni
grown
broth
contain
ampicillin
glucos
overnight
shake
rpm
small
inoculum
transfer
broth
contain
ampicillin
mgml
glucos
shake
rpm
till
od
reach
helper
phage
ad
plate
incub
without
shake
min
shake
rpm
cell
spun
g
supernat
discard
pellet
wash
broth
pellet
resuspend
broth
contain
ampicillin
mgml
kanamycin
mgml
glucos
shake
rpm
h
centrifug
g
supernat
collect
store
aliquot
test
phage
elisa
elisa
plate
coat
peptid
nahco
ph
incub
overnight
plate
wash
pb
block
nonfat
milk
titan
biotech
india
h
plate
wash
three
time
pb
phage
supernat
ad
well
incub
rt
phage
supernat
discard
plate
wash
four
time
pbst
anti
antibodi
dilut
ad
sigma
incub
rt
plate
wash
four
time
pbst
anti
rabbit
hrp
jackson
dilut
ad
incub
rt
plate
wash
four
time
pbst
tmb
substrat
ad
reaction
stop
ad
h
absorb
measur
individu
bacteri
coloni
grown
medium
contain
ampicillin
mgml
glucos
shake
rpm
till
od
reach
next
helper
phage
ad
incub
min
without
shake
follow
min
shake
rpm
cell
centrifug
g
min
supernat
discard
pellet
wash
broth
pellet
resuspend
broth
contain
ampicillin
mgml
kanamycin
mgml
glucos
shake
rpm
h
centrifug
g
min
supernat
transfer
glass
bottl
volum
pegnacl
ad
kept
ice
h
follow
centrifug
g
min
supernat
discard
pellet
dissolv
steril
autoclav
pb
store
transform
unit
tu
calcul
twenti
nine
scfv
clone
randomli
select
unselect
librari
sequenc
macrogen
south
korea
sequenc
analys
use
immunoglobulin
blast
v
base
softwar
divers
scfv
repertoir
analys
compar
restrict
digest
pattern
scfv
ten
clone
randomli
select
primari
phage
librari
plasmid
isol
scfv
sequenc
amplifi
use
primer
ptfw
cct
ttc
tat
gcg
gcc
cag
ccg
gcc
atg
gcc
ptrv
cag
tca
ttc
tcg
act
tgc
ggc
cgc
acg
min
anneal
extens
min
final
extens
min
amplifi
pcr
product
digest
frequent
cutter
restrict
enzym
neb
analys
agaros
gel
clone
show
positivitybind
phage
elisa
select
solubl
scfv
express
transform
use
calcium
chlorid
mediat
transform
solubl
scfv
express
cell
carri
plasmid
grown
ml
medium
overnight
shake
rpm
next
day
th
volum
overnight
cultur
inocul
litr
medium
grown
shake
rpm
till
od
reach
cultur
induc
mm
iptg
h
cell
harvest
differ
fraction
prepar
scfv
purifi
periplasm
fraction
briefli
cell
harvest
centrifug
g
min
supernat
discard
pellet
resuspend
mm
triscl
sucros
ph
ml
gram
wet
weight
cell
place
ice
min
mm
edta
ad
final
concentr
mm
edta
cell
spun
g
min
pellet
resuspend
mm
mgso
cell
place
ice
min
slowli
stir
pellet
g
min
supernat
collect
purif
purif
etag
scfv
carri
use
recombin
phage
antibodi
system
rpa
purif
modul
amersham
bioscienc
per
manufactur
instruct
periplasm
extract
filter
filter
remov
remain
cell
debri
anti
tag
column
regener
wash
column
elut
buffer
glycin
ph
equilibr
ml
bind
buffer
phosphat
buffer
nan
ph
etag
scfv
periplasm
extract
allow
bind
column
pass
extract
column
unbound
excess
e
coli
protein
remov
column
wash
ml
bind
buffer
flow
rate
step
maintain
mlmin
column
final
bound
scfv
elut
elut
buffer
sever
fraction
elut
scfv
collect
tube
contain
neutral
buffer
tri
ph
amount
protein
fraction
estim
use
bca
method
fraction
contain
consider
amount
scfv
pool
togeth
concentr
solubl
elisa
perform
describ
phage
elisa
hundr
microlit
solubl
scfv
periplasm
extractpurifi
scfv
ad
incub
room
temperatur
elisa
plate
wash
three
time
pbst
incub
dilut
primari
antibodi
mpb
plate
wash
three
time
pbst
incub
dilut
anti
rabbit
hrp
conjug
secondari
antibodi
mpb
elisa
plate
wash
describ
tmp
substrat
ad
incub
rt
till
colour
develop
reaction
stop
ad
absorb
read
nm
sdspage
done
describ
protein
separ
run
gel
stack
gel
visual
coomassi
brilliant
blue
cbb
stain
western
blot
gel
blot
onto
nitrocellulos
membran
use
electroblot
v
probe
primari
antibodi
antirabbit
hrp
use
secondari
antibodi
colour
develop
dab
substrat
